I-O Optimise: a multinational real-world research initiative in thoracic malignancies
S Ekman, F Griesinger, P Baas, D Chao, C Chouaid, JC O'Donnell, JR Penrod, M Daumont, L Lacoin, A McKenney, M Khovratovich, REJ Munro, I Durand-Zaleski, SP Johnsen
Future Oncol 2019;15:1551-1163
I-O Optimise® is an ongoing collaborative real-world research initiative focused on building a multinational data platform that leverages existing real-world data sources to provide ongoing, timely, and novel insights into real-world treatment patterns and outcomes in patients with lung cancer
View: Full publication summary
Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative
M Soares, L Antunes, P Redondo, M Borges, R Hermans, D Patel, F Grimson, R Munro, C Chaib, L Lacoin, M Daumont, JR Penrod, JC O'Donnell, MJ Bento, FR Goncalves
BMC Pulm Med. 2020;20:240. DOI: 10.1186/s12890-020-01270-z
This retrospective cohort study of 1,008 patients with incident advanced non-small cell lung cancer (NSCLC), as part of the I-O Optimise research initiative, evaluated real-world treatment patterns and survival prior to immunotherapy reimbursement at IPO-Porto hospital in Portugal (2012–2017).
View: Full publication summary
You may contact our EU Data Protection Officer at EUDPO@BMS.com to exercise any data privacy rights that you may have, as well as to raise any concerns or questions in relation to the handling of your personal data by Bristol‑Myers Squibb Company.
Home Corporate Website Contact
Sitemap Privacy Policy
Legal Notice
